ArticleClinical & translational immunology2020
A T-cell reporter platform for high-throughput and reliable investigation of TCR function and biology.
Article in Clinical & translational immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Balancing the efficacy and safety of chimeric antigen receptor T-cell therapy by affinity combination.Nature communications · 2026Article
- Metabolic quiescence of naive-like memory T cells precedes and maintains antigen-specific T cell memory.Nature immunology · 2026Article
- Tempered signal strength via low-dose MEK inhibition optimizes therapeutic performance of engineered T cells.Journal for immunotherapy of cancer · 2025Article
- MR1-ligand cross-linking identifies vitamin B6 metabolites as TCR-reactive antigens.Cell reports methods · 2025Article
- A bioluminescent reporter bioassay for in-process assessment of chimeric antigen receptor lentiviral vector potency.Antibody therapeutics · 2025Article
- Features of Highly Homologous T-Cell Receptor Repertoire in the Immune Response to Mutations in Immunogenic Epitopes.International journal of molecular sciences · 2024Article
- Predicting T cell receptor functionality against mutant epitopes.Cell genomics · 2024Article
- Dual role of the peptide-loading complex as proofreader and limiter of MHC-I presentation.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Dynamic monitoring of viral gene expression reveals rapid antiviral effects of CD8 T cells recognizing the HCMV-pp65 antigen.Frontiers in immunology · 2024Article
- Using the Jurkat reporter T cell line for evaluating the functionality of novel chimeric antigen receptors.Frontiers in molecular medicine · 2023Article
- A luminescence-based method to assess antigen presentation and antigen-specific T cell responses forFrontiers in immunology · 2023Article
- Expression of inducible factors reprograms CAR-T cells for enhanced function and safety.Cancer cell · 2022Article
- Gene Signatures of T-Cell Activation Can Serve as Predictors of Functionality for SARS-CoV-2-Specific T-Cell Receptors.Vaccines · 2022Article
- Review
- CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients.PloS one · 2022Article
- Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy.Cell reports. Medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTransgenic re-expression enables unbiased investigation of T-cell receptor (TCR)-intrinsic characteristics detached from its original cellular context. Recent advancements in TCR repertoire sequencing and development of protocols for direct cloning of full TCRαβ constructs now facilitate large-scale transgenic TCR re-expression. Together, this offers unprecedented opportunities for the screening of TCRs for basic research as well as clinical use. However, the functional characterisation of re-expressed TCRs is still a complicated and laborious matter. Here, we propose a Jurkat-based triple parameter TCR signalling reporter endogenous TCR knockout cellular platform (TPR
methodsAs a proof-of-concept, we transgenically re-expressed 59 human cytomegalovirus-specific TCRs and systematically investigated and compared TCR function in TPR
resultsWe demonstrate that the TPR
conclusionOverall, our data show that the TPR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.